scholarly journals Health conditions and quality of life in survivors of childhood acute myeloid leukemia comparing post remission chemotherapy to BMT: A report from the children's oncology group

2013 ◽  
Vol 61 (4) ◽  
pp. 729-736 ◽  
Author(s):  
Kris Ann P. Schultz ◽  
Lu Chen ◽  
Zhengjia Chen ◽  
Toana Kawashima ◽  
Kevin C. Oeffinger ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Health Conditions ◽  
Oncology Group ◽  
Childhood Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group

2019 ◽  
Vol 8 (9) ◽  
pp. 4454-4464 ◽  
Author(s):  
Rajaram Nagarajan ◽  
Robert Gerbing ◽  
Todd Alonzo ◽  
Donna L. Johnston ◽  
Richard Aplenc ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Oncology Group ◽  
Pediatric Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals Quality of Life in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4841-4841
Author(s):  
Rajaram Nagarajan ◽  
Todd A Alonzo ◽  
Robert B Gerbing ◽  
Donna Johnston ◽  
Richard Aplenc ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Acute Myeloid Leukemia ◽  
Physical Health ◽  
Myeloid Leukemia ◽  
Oncology Group ◽  
Pediatric Acute Myeloid Leukemia ◽  
Grade 3 ◽  
To Receive ◽  
Acute Myeloid

Abstract Background: Objectives were to describe guardian proxy-reported quality of life (QoL) during chemotherapy for pediatric acute myeloid leukemia (AML) and to identify treatment and demographic factors associated with worse QoL. Methods: Children's Oncology Group phase 3 AAML1031 study was a randomized trial for de novo AML patients age 0-30 to receive standard AML therapy with and without bortezomib. Patients with high risk FLT3-internal tandem duplication high allelic ratio (ITD HAR) were allocated to receive sorafenib in addition to the standard chemotherapy. Patients enrolled on the AAML1031 study who were 2-18 years of age at diagnosis with English or Spanish-speaking guardians were eligible to participate in the QoL portion of the study which included the PedsQL 4.0 Generic Core Scales, PedsQL 3.0 Acute Cancer Module and PedsQL Multidimensional Fatigue Scale. QoL assessments were obtained at four timepoints - at diagnosis and following completion of second, third and fourth (final) course of therapy. Guardians provided proxy assessments for all patients, while self-report for patients 5 years of age or older who could understand English was optional. This analysis focused on guardian proxy-reported QoL for patients who did not have FLT3-ITD HAR. In addition to demographic and treatment related factors, the total number of non-hematological grade 3-4 CTCAE (Common Terminology Criteria for Adverse Events) toxicities occurring during the time frame of QoL assessments was examined as a potential predictor of QoL. Results: There were a total of 4105 QoL submissions and there were 3513 non-hematological grade 3-4 CTCAE toxicities reported: 1339 submissions at diagnosis with 1088 toxicities reported, 1112 submissions following the second course with 721 toxicities, 929 submissions following third course with 911 toxicities, and 725 submissions following the fourth course with 793 toxicities. In repeated measures linear regression the number of submitted CTCAE toxicities was significantly associated with worse physical health (β±standard error (SE) -3.00±0.69; P<0.001) and general fatigue (β±SE -2.50±0.66; P<0.001). Older age was significantly associated with general fatigue (β±SE -0.58±0.25; P=0.022). In contrast, gender, risk status, bortezomib assignment, duration of neutropenia, private insurance status, white race and Hispanic ethnicity were not associated with physical health, psychosocial health or fatigue. Conclusions: The number of CTCAE toxicities was an important factor influencing physical QoL and fatigue among children on treatment for AML. Identifying novel approaches for reducing toxicities should be a priority to potentially improve QoL. Disclosures No relevant conflicts of interest to declare.

Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.

1996 ◽  
Vol 14 (4) ◽  
pp. 1345-1352 ◽  
Author(s):  
E J Bow ◽  
J A Sutherland ◽  
M G Kilpatrick ◽  
G J Williams ◽  
J J Clinch ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
The Elderly ◽  
Remission Induction ◽  
Cell Phenotype ◽  
Induction Regimen ◽  
Acute Myeloid ◽  
Stem Cell Phenotype

PURPOSE The University of Manitoba Adult Acute Leukemia Study Group sought to examine the safety, efficacy, and impact on quality of life of a non-cytarabine-containing remission-induction regimen followed by intermediate-dose cytarabine (IDARA-C) postremission therapy for the management of untreated acute myeloid leukemia (AML) in patients age 60 to 80 years. PATIENTS AND METHODS Eligible patients received mitoxantrone 10 mg/m2 and etoposide 100 mg/m2 on days 1 to 5. Complete remitters received a single course of cytarabine 0.5 mg/m2 every 12 hours on days 1 to 6. Cytogenetic and immunophenotyping studies were performed at diagnosis and were examined for prognostic importance. The Functional Living Index-Cancer (FLI-C) was used in the longitudinal assessment of quality of life. RESULTS A total of 37 (55%) of 67 eligible patients achieved remission, 34 (92%) of whom did so with a single course. The induction mortality rate was 12%. The median disease-free and overall survival times were 8.4 and 9.2 months, respectively. CD34 stem-cell phenotype, poor performance status, and high cytogenetic complexity score were independent covariates of failure to achieve remission. Very complex karotype combined with CD34 stem-cell phenotype to predict induction death in 67% of cases (P = .0003). Cytotoxic therapy-related gut epithelial damage was maximal during weeks 2 and 3 of therapy. Complete remitters and partial responders exhibited significantly improved global FLI-C scores following completion of therapy. CONCLUSION Mitoxantrone plus etoposide was an effective and well-tolerated first-line induction regimen for AML in the elderly that should be studied further in comparison to the standard cytarabine/anthracycline-based therapy.

Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia

2009 ◽  
Vol 69 (2) ◽  
pp. 168-174 ◽  
Author(s):  
Shabbir M.H. Alibhai ◽  
Marc Leach ◽  
Vikas Gupta ◽  
George A. Tomlinson ◽  
Joseph M. Brandwein ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Older Adults ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Acute Myeloid

Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia

2013 ◽  
Vol 37 (3) ◽  
pp. 274-279 ◽  
Author(s):  
Filgen Y. Fung ◽  
Madeline Li ◽  
Henriette Breunis ◽  
Narhari Timilshina ◽  
Mark D. Minden ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Cytokine Levels ◽  
Acute Myeloid

Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy

Leukemia ◽  
2019 ◽  
Vol 33 (10) ◽  
pp. 2393-2402 ◽  
Author(s):  
Areej El-Jawahri ◽  
Gregory A. Abel ◽  
Lara Traeger ◽  
Lauren Waldman ◽  
Netana Markovitz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Acute Myeloid Leukemia ◽  
Older Patients ◽  
Myeloid Leukemia ◽  
Intensive Chemotherapy ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document